AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$TENX

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $1.8M of TENX (indirect holdings)

ADAR1 Capital Management, LLC purchased 1,025,867 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.77 ($1.75–$1.78, $1.81M total) across 3 trades over 2026-08-20 to 2026-08-24. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting
SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel
Published Aug 24, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TENX
Bullish
medium confidence
Mentioned
$TENX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TENXBullishLow
01

Why it matters

The purchase adds to insider confidence but limited in scale.

02

Market read

Insider buying may provide a modest bullish cue for TENX traders.

03

What to watch

The purchase size is small relative to market cap; broader market conditions may dominate price movement.

Relevance 7/10Novelty 7/10Timing: filed today

Background

SEC Form 4 filing reveals insider transaction for Tenax Therapeutics.

Company-level read

Ticker impact

$TENXBullishMedium confidence
Context

Form 4 disclosed ADAR1 Capital Management purchased 1.03M shares of Tenax Therapeutics for $1.8M, increasing its stake to 4.85M shares.

Expected impact

Potential modest price lift in the near term.

Evidence & confidence

10% owner increased holdings by $1.8M; while amount is modest, insider stake signals bullish sentiment.

Market effects

Sector

May indicate confidence in biotech sector pipeline.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong signal.

Key entities

  • Company
    Tenax Therapeutics, Inc.

    Biopharmaceutical company listed on NASDAQ.

  • Investor
    ADAR1 Capital Management, LLC

    Investment manager and 10% owner of Tenax.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TENX insider trading history →

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min